Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$41.99 - $62.38 $520,676 - $773,512
-12,400 Reduced 22.67%
42,300 $2.49 Million
Q3 2023

Nov 14, 2023

SELL
$27.8 - $45.35 $55,600 - $90,700
-2,000 Reduced 3.53%
54,700 $2.38 Million
Q2 2023

Aug 14, 2023

SELL
$36.13 - $49.49 $502,207 - $687,911
-13,900 Reduced 19.69%
56,700 $2.05 Million
Q1 2023

May 15, 2023

SELL
$36.54 - $54.26 $3.15 Million - $4.67 Million
-86,100 Reduced 54.95%
70,600 $2.62 Million
Q4 2022

Feb 14, 2023

BUY
$41.27 - $98.62 $2.72 Million - $6.49 Million
65,800 Added 72.39%
156,700 $7.1 Million
Q3 2022

Nov 14, 2022

BUY
$59.5 - $86.7 $1.43 Million - $2.09 Million
24,100 Added 36.08%
90,900 $6.35 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.